ABBV AbbVie Inc Earnings per share for the last twelve months

Corporate company logo of AbbVie Corp. (ABBV)

AbbVie Inc. (ABBV) offsets patent expirations by launching innovative drugs, thereby maintaining its market position. The rolling trailing twelve-month earnings per share illustrates this resilience, where 5.81 characterizes this valuation metric. High-cost biologics delivery ensures product integrity, while the implementation of environmental standards and ethical management minimizes the production's environmental impact.

ABBV (AbbVie Corp.) Earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Financial and market metric breakdowns for Abbvie (ABBV)

- current quotes and average value forecast:
- market capitalization data:
Comprehensive company analysis:abbvie.com (ABBV)
Mass-produced product of AbbVie Inc

The selection of high-quality issuers is based on an analysis of return on equity, where the key criterion is the efficiency of profit generation per ordinary share. This fundamental earnings per share (EPS) TTM reflects the total income distributed across all outstanding shares, allowing for an assessment of AbbVie Inc. (ABBV) and its success in integrating new biotech startups and offsetting patent losses through the dynamics of this indicator.